Dec. 25 at 5:11 PM
$VXRT $DVAX $SNY This is what Sanofi obtained on top of Dvax itself, an exclusive licensing deal for an oral Covid Vaccine tablet from Vaxart:
Under the terms of the license agreement:
$700M Potential + Royalties to Vaxart.
Dynavax will pay Vaxart an upfront license fee of
$25 million and make a
$5 million equity investment in Vaxart at a per share price premium to market pursuant to the terms of a securities purchase agreement.
In addition, after receiving the results of the Phase 2b clinical trial, Dynavax will pay an additional fee of
$50 million to Vaxart , unless Dynavax.
In addition, if Dynavax elects to assume responsibility for the continued development of the oral COVID-19 program, Vaxart may be entitled to receive up to
$195 million in potential future regulatory milestone payments, up to
$425 million in potential future net sales milestone payments, and tiered royalties at rates in the low-to-mid teens on potential future net sales.
